Consumer drug advertising is favorite culprit in rising Rx costs

Share this article:

Consumer drug advertising remains corporate benefit managers' favorite culprit in rising prescription drug costs, according to an Arxcel survey. Forty-five percent cited DTC as the top cause of rising costs, compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%, and an aging population ranked third, at 17%. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters